EP0859771A4 - Substituierte pyridylpyrrole, solche verbindungen enthaltende zubereitungen und verfahren zu deren nutzung - Google Patents

Substituierte pyridylpyrrole, solche verbindungen enthaltende zubereitungen und verfahren zu deren nutzung

Info

Publication number
EP0859771A4
EP0859771A4 EP96942022A EP96942022A EP0859771A4 EP 0859771 A4 EP0859771 A4 EP 0859771A4 EP 96942022 A EP96942022 A EP 96942022A EP 96942022 A EP96942022 A EP 96942022A EP 0859771 A4 EP0859771 A4 EP 0859771A4
Authority
EP
European Patent Office
Prior art keywords
compounds
compositions containing
substituted pyridyl
pyrroles
pyridyl pyrroles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96942022A
Other languages
English (en)
French (fr)
Other versions
EP0859771A1 (de
Inventor
Laszlo Stephen E De
Linda L Chang
Dooseop Kim
Nathan B Mantlo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605158.6A external-priority patent/GB9605158D0/en
Priority claimed from GBGB9612062.1A external-priority patent/GB9612062D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0859771A1 publication Critical patent/EP0859771A1/de
Publication of EP0859771A4 publication Critical patent/EP0859771A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP96942022A 1995-10-31 1996-10-30 Substituierte pyridylpyrrole, solche verbindungen enthaltende zubereitungen und verfahren zu deren nutzung Withdrawn EP0859771A4 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US15565 1979-02-26
US710095P 1995-10-31 1995-10-31
US7100P 1995-10-31
GB9605158 1996-03-12
GBGB9605158.6A GB9605158D0 (en) 1996-03-12 1996-03-12 Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
US1556596P 1996-04-18 1996-04-18
GBGB9612062.1A GB9612062D0 (en) 1996-06-10 1996-06-10 Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
GB9612062 1996-06-10
PCT/US1996/018539 WO1997016442A1 (en) 1995-10-31 1996-10-30 Substituted pyridyl pyrroles, compositions containing such compounds and methods of use

Publications (2)

Publication Number Publication Date
EP0859771A1 EP0859771A1 (de) 1998-08-26
EP0859771A4 true EP0859771A4 (de) 2000-03-15

Family

ID=27451424

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96942022A Withdrawn EP0859771A4 (de) 1995-10-31 1996-10-30 Substituierte pyridylpyrrole, solche verbindungen enthaltende zubereitungen und verfahren zu deren nutzung

Country Status (4)

Country Link
EP (1) EP0859771A4 (de)
JP (1) JPH11514651A (de)
AU (1) AU702887B2 (de)
WO (1) WO1997016442A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
EP0912548A1 (de) * 1996-07-11 1999-05-06 Pfizer Inc. Pyridylpyrrol-derivate verwendbar als interleukin- und tnf- antagonisten
ES2215242T3 (es) 1996-11-19 2004-10-01 Amgen Inc. Agentes antiinflamatorios de pirrol condensado sustituido con arilo y heteroarilo.
TW520362B (en) * 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
BR9713863A (pt) * 1996-12-05 2000-03-14 Amgen Inc Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processos de profilaxia ou tratamento, para abaixar as concentrações no plasma, para diminuir a produção de prostaglandinas, e, para diminuir a atividade de enzima ciclooxigenase
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
EP1314732A3 (de) * 1996-12-05 2004-01-02 Amgen Inc. Substituierte Pyrimidinverbindungen und ihre Verwendung
PT988301E (pt) 1997-06-12 2006-10-31 Aventis Pharma Ltd Acetais ciclicos de imidazolilo
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO1999001423A1 (en) * 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
EP1473292A1 (de) * 1997-11-03 2004-11-03 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatische heterocyclische Verbindungen als antiinflammatorische Mittel
EP1028953A1 (de) 1997-11-03 2000-08-23 Boehringer Ingelheim Pharmaceuticals Inc. Aromatische heterocyclische verbindungen als antiinflammatorische mittel
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
AU1924699A (en) 1997-12-19 1999-07-12 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
KR20010034114A (ko) * 1998-01-14 2001-04-25 니뽄 신야쿠 가부시키가이샤 칼륨 채널 활성화제
ATE229015T1 (de) * 1998-05-12 2002-12-15 Wyeth Corp Zur behandlung von insulin-resistenz und hyperglycemie geeignete biphenyl-oxo-essigsäuren
US6232322B1 (en) 1998-05-12 2001-05-15 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6649617B1 (en) 1998-10-07 2003-11-18 Smithkline Beecham Corporation Treatment for stroke management
DE19847823A1 (de) * 1998-10-16 2000-04-20 Aventis Pharma Gmbh Substituierte Thiadiazolsulfonamide
ATE258055T1 (de) 1998-11-04 2004-02-15 Smithkline Beecham Corp Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
DE60023853T2 (de) 1999-03-12 2006-05-24 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
WO2000066124A1 (fr) * 1999-04-28 2000-11-09 Sankyo Company, Limited Agents preventifs ou inhibiteurs destines a une hepatopathie
US6310081B1 (en) 1999-05-10 2001-10-30 American Home Products Corporation Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
PT1178981E (pt) * 1999-05-14 2003-11-28 Ortho Mcneil Pharm Inc 3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
EP1200411B1 (de) 1999-07-09 2005-12-14 Boehringer Ingelheim Pharmaceuticals Inc. Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
ATE312095T1 (de) * 1999-09-14 2005-12-15 Merck Frosst Canada Inc Carbonsäuren und acylsulfonamide, diese verbindungen enthaltende zubereitungen und behandlungsmethoden
US6900043B1 (en) 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
WO2001032658A1 (en) * 1999-11-02 2001-05-10 Ajinomoto Co., Inc. Polyazanaphthalene compound and medicinal use thereof
JP4955171B2 (ja) 1999-11-16 2012-06-20 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての尿素誘導体
ES2249309T3 (es) 1999-11-23 2006-04-01 Smithkline Beecham Corp Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
WO2001038314A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
EP1741445B1 (de) 2000-01-21 2013-08-14 Novartis AG Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP1345890A1 (de) 2000-11-17 2003-09-24 Novo Nordisk A/S Glucagon-antagonisten/inverse agonisten
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
EP1352906A4 (de) * 2001-01-18 2004-06-16 Sankyo Co Zusammensetzungen für die prävention bzw. behandlung von lebererkrankungen
WO2002057255A1 (en) * 2001-01-22 2002-07-25 Sankyo Company, Limited 4- or 5-substituted pyrrole derivatives
MY130778A (en) 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
CA2445003A1 (en) 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
JP2004531571A (ja) 2001-05-25 2004-10-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
IL160442A0 (en) * 2001-08-28 2004-07-25 Leo Pharma As Novel aminobenzophenones
WO2003022832A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans and pyrroles as raf kinase inhibitors
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
JP4629978B2 (ja) 2002-02-25 2011-02-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン媒介疾患の治療に有用な１，４−二置換ベンゾ縮合シクロアルキル尿素化合物
ES2278170T3 (es) 2002-07-09 2007-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
US20050043331A1 (en) * 2002-09-27 2005-02-24 Bullington James L. Substituted 3-(2,5-disubstituted)pyridyl-4-aryl pyrroles for treating inflammatory diseases
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
DE602004030318D1 (de) 2003-01-27 2011-01-13 Merck Sharp & Dohme Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
US7301036B2 (en) 2003-12-19 2007-11-27 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
ATE395338T1 (de) 2004-06-04 2008-05-15 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
EP1773330B1 (de) 2004-07-22 2010-05-26 Merck Sharp & Dohme Corp. Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
JP2008533200A (ja) 2005-03-21 2008-08-21 メルク エンド カムパニー インコーポレーテッド 置換アリールおよびヘテロアリール誘導体、かかる化合物を含有する組成物および使用法
WO2006104826A2 (en) 2005-03-30 2006-10-05 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AU2006276072A1 (en) 2005-07-26 2007-02-08 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
CA2622608C (en) 2005-09-14 2014-08-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
AU2006294579A1 (en) 2005-09-27 2007-04-05 Myriad Genetics, Inc. Pyrrole derivatives as therapeutic compounds
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
EP2001472A2 (de) 2006-03-23 2008-12-17 Merck and Co., Inc. Glucagon-rezeptor-antagonisten-verbindungen, zusammensetzungen mit solchen verbindungen und verfahren zu ihrer verwendung
WO2007124181A2 (en) 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
JP2009537525A (ja) 2006-05-16 2009-10-29 メルク エンド カムパニー インコーポレーテッド グルカゴン受容体アンタゴニスト化合物、このような化合物を含む組成物及び使用方法
CA2656507C (en) 2006-07-17 2012-03-20 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
ATE501124T1 (de) 2006-09-05 2011-03-15 Amgen Inc Phthalazin-, aza- und diazaphthalazinverbindungen und anwendungsverfahren
JP2010504295A (ja) 2006-09-21 2010-02-12 ノバルティス アーゲー サイトカイン介在疾患の処置に有用なピロール誘導体
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AU2007307031B2 (en) 2006-10-11 2011-11-24 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use therof
CN101622229B (zh) * 2007-02-26 2013-02-27 参天制药株式会社 具有脲基和氨基羰基作为取代基的吡咯衍生物
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
US8314131B2 (en) 2007-09-21 2012-11-20 Amgen Inc. Triazole fused heteroaryl compounds and methods of use thereof
WO2010025202A1 (en) 2008-08-29 2010-03-04 Amgen Inc. PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
EP2334674B1 (de) 2008-08-29 2012-06-06 Amgen, Inc Pyridazinopyridinonverbindungen zur Behandlung von durch Proteinkinase vermittelten Krankheiten
US8497269B2 (en) 2008-10-10 2013-07-30 Amgen Inc. Phthalazine compounds as p38 map kinase modulators and methods of use thereof
WO2010042646A1 (en) 2008-10-10 2010-04-15 Amgen Inc. Aza- and diaza-phthalazine compounds as p38 map kinase modulators and methods of use thereof
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
SI2531501T1 (sl) 2010-02-03 2014-04-30 Takeda Pharmaceutical Company Limited Inhibitorji kinaze-1, ki regulirajo signal apoptoze
WO2012085745A1 (en) 2010-12-23 2012-06-28 Pfizer Inc. Glucagon receptor modulators
PT2673260T (pt) 2011-02-08 2016-10-24 Pfizer Modulador do recetor de glucagon
JP5647379B2 (ja) 2011-07-22 2014-12-24 ファイザー・インク キノリニルグルカゴン受容体モジュレーター
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
IT201800003680A1 (it) * 2018-03-16 2019-09-16 Univ Degli Studi Di Siena Composti antivirali e usi di essi

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2113861A1 (de) * 1970-11-16 1972-06-30 Pfizer
EP0034798A2 (de) * 1980-02-19 1981-09-02 E.I. Du Pont De Nemours And Company Entzündungshemmende 4,5-Diaryl-2-(substituierte thio)-Pyrrole und ihre übereinstimmenden Sulfoxyde und Sulfone
WO1993014081A1 (en) * 1992-01-13 1993-07-22 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267185A (en) * 1980-04-09 1981-05-12 E. I. Du Pont De Nemours And Company Antidepressant pyrrolylpiperidines, their pharmaceutical compositions and method of use
US4652582A (en) * 1985-01-09 1987-03-24 E. I. Du Pont De Nemours And Company Antiinflammatory-2-halo-4,5-diarylpyrroles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2113861A1 (de) * 1970-11-16 1972-06-30 Pfizer
EP0034798A2 (de) * 1980-02-19 1981-09-02 E.I. Du Pont De Nemours And Company Entzündungshemmende 4,5-Diaryl-2-(substituierte thio)-Pyrrole und ihre übereinstimmenden Sulfoxyde und Sulfone
WO1993014081A1 (en) * 1992-01-13 1993-07-22 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KONAKAHARA, TAKEO ET AL: "One-pot synthesis of pyrroles from N-silyl-1-azaallyl anions", HETEROCYCLES ( 1993 ), 35(2), 1171-84, 1993, XP000857214 *
See also references of WO9716442A1 *
SILVESTRI, G. ET AL: "Electrochemical oxidation of 2,4,5-triaryl-substituted pyrroles. II. Oxidative dimerization of 4,5-diphenyl-2-mesitylylpyrrole", J. HETEROCYCL. CHEM. ( 1989 ), 26(2), 489-92, 1989, XP000857212 *
SILVESTRI, G. ET AL: "Electrochemical oxidation of substituted pyrroles. IV. The influence of soluble bases", J. HETEROCYCL. CHEM. ( 1992 ), 29(7), 1847-50, 1992, XP000857213 *

Also Published As

Publication number Publication date
AU1120897A (en) 1997-05-22
EP0859771A1 (de) 1998-08-26
AU702887B2 (en) 1999-03-11
JPH11514651A (ja) 1999-12-14
WO1997016442A1 (en) 1997-05-09

Similar Documents

Publication Publication Date Title
EP0859771A4 (de) Substituierte pyridylpyrrole, solche verbindungen enthaltende zubereitungen und verfahren zu deren nutzung
EP0871444A4 (de) 2,5 substituierte aryl pyrrol, dieses enthaltende zusammensetzungen und dessen verwendung
EP0948257A4 (de) Triaryl-substituierte imidazole, sie enthaltende zusammensetzungen und verfahren zu ihrer verwendung
MA23961A1 (fr) Benzylaminopiperidines substituees et compositions les contenant
SI0807111T1 (en) Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same
PL323470A1 (en) Application of n-propargil-1-amidoindane (r)-enantionmer, its salts and compositions containing same
EP0746301A4 (de) Selbstbräunende kosmetische mittel und verfahren für ihre verwendung
MA24158A1 (fr) Derives d'imidazole substitues, procede pour leur preparation et compositions les contenant
FI940680A7 (fi) Menetelmä sulfamoyyli- ja amidinoryhmän sisältävien yhdisteiden valmistamiseksi
FR2703993B1 (fr) Utilisation en cosmétique de dérivés lipophiles des amino déoxyalditols, compositions cosmétiques les contenant, et nouveaux carbamates d'alkyle.
PL327405A1 (en) Novel taxoids, method of obtaining them and pharmaceutic compositions containing such compounds
FI972309A7 (fi) 2-heterosyklyylioksi- ja tiometyyli-1,2,5-tiaditsolidin-3-oni-1,1-diok sideja, niitä sisältäviä koostumuksia ja menetelmä niiden valmistamise ksi
EP1015430A4 (de) Spiro (prrolidin-2,3'-oxoindol)-verbindungen und verfahren zu ihrer anwendung
DE69124769D1 (de) Verfahren zur Herstellung von (1'R,3S)-3-(1'-hydroxy-ethyl)-Azetidin-2-on und deren Derivaten
FI935825L (fi) 2,4-substituoidut 5-(N-substituoitu-sulfamoyyli)-bentsoyyliguanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
FR2749504B1 (fr) Composition de suspension pour produit cosmetique et procede d'utilisation de celui-ci
FR2731706B1 (fr) Composes heterocycliques aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
EP0604024A3 (de) Reaktive Tintenzusammensetzungen und System.
FR2731151B1 (fr) Composition colorante pour cheveux contenant un broyat de racines d'impatiens balsamina, et son application
FR2730995B1 (fr) Composes bi-aromatiques derives d'amide, compositions pharmaceutiques et cosmetiques les contenant et utilisations
IL117808A (en) 1, 3-dihydro-1-(phenylalkenyl)- 2h-imidazol-2-one derivatives, their preparation and pharmaceutical compositions containing them
FI972306L (fi) Substituoituja 2-aryylikarbonyylioksimetyyli-1,2,5-tiadiatsolidin -3- oni-1,1-dioksidi-johdannaisia ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
FR2732019B1 (fr) Spiropyrannes photochromiques, compositions et articles les contenant
EP0750620A4 (de) Carbapenem-derivate, zusammensetzungen und behandlungsmethoden
IL117806A0 (en) 1,3-Dihydro-2h-imidazol-2-one derivatives their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980602

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 401/04 A, 7A 61K 31/44 B, 7C 07D 403/04 B, 7C 07D 409/14 B, 7C 07D 407/14 B, 7C 07D 401/14 B, 7C 07D 413/14 B, 7C 07D 417/14 B, 7C 07D 401/04 J, 7C 07D 213:00 J, 7C 07D 207:00 J

A4 Supplementary search report drawn up and despatched

Effective date: 20000128

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20000823

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030510